Aandeel ALRN AILERON THERAPEUTICS, INC.
Toevoegen aan een lijst
Om deze functie te gebruiken moet u een klant of lid zijn.
InloggenRegistreren

Andere talen Aileron Therapeutics, Inc.

Aandelen

ALRN

US00887A2042

Beurs gesloten - Nasdaq
Andere beurzen
 22:30:00 06-05-2024 		Variatie 5 dagen Verschil t.o.v. 1 jan (%)
3,95 USD +5,05% Intraday-grafiek van Aileron Therapeutics, Inc. -19,72% +29,57%
03/05 Aileron Therapeutics sluit direct aanbod van aandelen en warrants af MT
01/05 Transcript : Aileron Therapeutics, Inc. - Special Call

Andere talen

Zoeken op
Resultaten bekijken
Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!
Gratis inschrijven
Aileron Therapeutics to Present at Two Upcoming Investor Conferences
Aileron Therapeutics Closes Direct Offering of Shares, Warrants
Aileron Therapeutics Announces Closing of Underwritten Registered Direct Offering of up to Approximately $40 Million
Aileron Therapeutics Announces Pricing of Underwritten Registered Direct Offering Priced At-The-Market Under Nasdaq Rules of up to Approximately $40 Million
Aileron Therapeutics Announces Positive Data from Cohort 1 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)
Aileron Therapeutics, Inc. Announces Positive Data from Cohort 1 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis
Aileron Therapeutics : Corporate Presentation April 2024
Aileron Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Aileron Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Aileron Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
Aileron Therapeutics : Management Change/Compensation - Form 8-K
Aileron Therapeutics, Inc. Announces CFO Changes
Aileron Therapeutics, Inc. Announces Board Changes
Aileron Therapeutics Names Brian Windsor as CEO
Aileron Therapeutics Announces CEO Transition
Aileron Therapeutics, Inc. Announces Appointment of Brian Windsor as President and to the Board of Directors
Aileron Therapeutics, Inc. Announces CEO Changes
Aileron Therapeutics, Inc. Announces Resignation of Nolan Sigal, M.D., Ph.D. from Board of Directors, Member of Nominating and Corporate Governance Committee
Aileron Therapeutics and Pulmonary Care Experts To Discuss the Potential Implications of LTI-03 for Idiopathic Pulmonary Fibrosis in Virtual Key Opinion Leader Event
Aileron Therapeutics to Host Key Opinion Leader Event on February 15, 2024
Geen resultaten voor deze zoekopdracht
Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Filters

Zoeken op

Datum van publicatie

Sinds de

Tot

  1. Beurs
  2. Aandelen
  3. Koers ALRN
  4. Nieuws Aileron Therapeutics, Inc.
  5. Andere talen